At the news
? BEARISHIMPACT 6/10 SC 13D/A filed Nov 12, 2026 at 16:34 ET
Lantheus Holdings (via its subsidiary Lantheus Alpha Therapy) filed Amendment No. 4 to its Schedule 13D, reporting a reduction in its stake in Perspective Therapeutics from above 5% to 3.9% (4,739,011 shares). The filing discloses open-market sales of 1,000,000 shares on October 5, 2026 at $2.75/share and 3,000,000 shares on November 10, 2026 at $0.80/share. The Reporting Persons state this is the final amendment and an exit filing, signaling they have ceased to be a 5% beneficial owner and are no longer actively engaged as an activist holder.
- Lantheus Alpha Therapy sold 1,000,000 shares on Oct 5, 2026 at avg $2.75/share and 3,000,000 shares on Nov 10, 2026 at avg $0.80/share.
- Beneficial ownership reduced to 4,739,011 shares (3.9% of 120,758,815 shares outstanding as of Nov 4, 2026).
- Filing is designated as the final amendment and exit filing; Lantheus no longer a 5% holder.
- Sales occurred just after Q3 2026 earnings (Nov 9, 2026) which reported a wider net loss of $32.4M.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access